170 related articles for article (PubMed ID: 37190270)
1. Antibiotics Significantly Decrease the Survival of Head and Neck Carcinoma Patients with Immunotherapy: A Real-World Analysis of More Than 3000 Cases.
Preissner S; Heiland M; Preissner R; Wirth M; Wollenberg B
Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190270
[TBL] [Abstract][Full Text] [Related]
2. Ibuprofen Reduces 5-Year Overall Survival of Head and Neck Cancer Patients With Immunotherapy - A Retrospective Case-controlled Real-World Data Analysis of 10,000 Patients.
Ebeling M; Derka S; Baudrexl J; Sakkas A; Scheurer M; Wilde F; Schramm A; Pietzka S
Anticancer Res; 2024 Jan; 44(1):313-322. PubMed ID: 38159991
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the Risk of Oral Squamous Cell Carcinoma in Patients with and without Recurrent Aphthous Stomatitis: A Retrospective Evaluation of Real-World Data of about 150,000 Patients.
Hertel M; Birinci S; Heiland M; Preissner R; Nahles S; Schmidt-Westhausen AM; Preissner S
Cancers (Basel); 2022 Dec; 14(23):. PubMed ID: 36497491
[TBL] [Abstract][Full Text] [Related]
4. Comparison of five-year survival rates among patients with oral squamous cell carcinoma with and without association with syphilis: a retrospective case-control study.
Hertel M; Hagedorn L; Schmidt-Westhausen AM; Dommisch H; Heiland M; Preissner R; Preissner S
BMC Cancer; 2022 Apr; 22(1):454. PubMed ID: 35468757
[TBL] [Abstract][Full Text] [Related]
5. The risk of oral squamous cell carcinoma in patients with and without somatoform disorders including bruxism: A retrospective evaluation of 309,278 individuals.
Heym M; Heiland M; Preissner R; Huebel C; Nahles S; Schmidt-Westhausen AM; Preissner S; Hertel M
Front Oncol; 2022; 12():1080492. PubMed ID: 36698388
[TBL] [Abstract][Full Text] [Related]
6. The association between body mass index and efficacy of pembrolizumab as second-line therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma.
Zhang X; Rui M; Lin C; Li Z; Wei D; Han R; Ju H; Ren G
Cancer Med; 2023 Feb; 12(3):2702-2712. PubMed ID: 35975731
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials.
Poulose JV; Kainickal CT
World J Clin Oncol; 2022 May; 13(5):388-411. PubMed ID: 35662989
[TBL] [Abstract][Full Text] [Related]
8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
9. FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy.
Larkins E; Blumenthal GM; Yuan W; He K; Sridhara R; Subramaniam S; Zhao H; Liu C; Yu J; Goldberg KB; McKee AE; Keegan P; Pazdur R
Oncologist; 2017 Jul; 22(7):873-878. PubMed ID: 28533473
[TBL] [Abstract][Full Text] [Related]
10. Association of Oral Microbiome With Risk for Incident Head and Neck Squamous Cell Cancer.
Hayes RB; Ahn J; Fan X; Peters BA; Ma Y; Yang L; Agalliu I; Burk RD; Ganly I; Purdue MP; Freedman ND; Gapstur SM; Pei Z
JAMA Oncol; 2018 Mar; 4(3):358-365. PubMed ID: 29327043
[TBL] [Abstract][Full Text] [Related]
11. Statin Medication Improves Five-Year Survival Rates in Patients with Head and Neck Cancer: A Retrospective Case-Control Study of about 100,000 Patients.
Wüster J; Heiland M; Nahles S; Preissner R; Preissner S
Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370705
[TBL] [Abstract][Full Text] [Related]
12. Effect of prior antibiotic or chemotherapy treatment on immunotherapy response in non-small cell lung cancer.
Nyein AF; Bari S; Hogue S; Zhao Y; Maller B; Sha S; Gomez MF; Rollison DE; Robinson LA
BMC Cancer; 2022 Jan; 22(1):101. PubMed ID: 35073876
[TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials.
Theelen WSME; Chen D; Verma V; Hobbs BP; Peulen HMU; Aerts JGJV; Bahce I; Niemeijer ALN; Chang JY; de Groot PM; Nguyen QN; Comeaux NI; Simon GR; Skoulidis F; Lin SH; He K; Patel R; Heymach J; Baas P; Welsh JW
Lancet Respir Med; 2021 May; 9(5):467-475. PubMed ID: 33096027
[TBL] [Abstract][Full Text] [Related]
14. A retrospective case-control study for the comparison of 5-year survival rates: the role of adjuvant and neoadjuvant chemotherapy in craniofacial bone sarcoma in adults.
Hofmann E; Preissner S; Hertel M; Preissner R; Rendenbach C; Flörcken A; Heiland M
Ther Adv Med Oncol; 2023; 15():17588359221148023. PubMed ID: 36818689
[TBL] [Abstract][Full Text] [Related]
15. Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy.
Buti S; Bersanelli M; Perrone F; Bracarda S; Di Maio M; Giusti R; Nigro O; Cortinovis DL; Aerts JGJV; Guaitoli G; Barbieri F; Ferrara MG; Bria E; Grossi F; Bareggi C; Berardi R; Torniai M; Cantini L; Sforza V; Genova C; Chiari R; Rocco D; Della Gravara L; Gori S; De Tursi M; Di Marino P; Mansueto G; Zoratto F; Filetti M; Citarella F; Russano M; Mazzoni F; Garassino MC; De Toma A; Signorelli D; Gelibter A; Siringo M; Follador A; Bisonni R; Tuzi A; Minuti G; Landi L; Ricciardi S; Migliorino MR; Tabbò F; Olmetto E; Metro G; Adamo V; Russo A; Spinelli GP; Banna GL; Addeo A; Friedlaender A; Cannita K; Porzio G; Ficorella C; Carmisciano L; Pinato DJ; Mazzaschi G; Tiseo M; Cortellini A
Eur J Cancer; 2021 Jun; 150():224-231. PubMed ID: 33934059
[TBL] [Abstract][Full Text] [Related]
16. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial.
Fakhry C; Westra WH; Li S; Cmelak A; Ridge JA; Pinto H; Forastiere A; Gillison ML
J Natl Cancer Inst; 2008 Feb; 100(4):261-9. PubMed ID: 18270337
[TBL] [Abstract][Full Text] [Related]
17. Short-course pembrolizumab and continuous afatinib therapy for recurrent or metastatic head and neck squamous cell carcinoma: a real-world data analysis.
Kao HF; Huang HC; Liao BC; Hong RL
BMC Cancer; 2022 Nov; 22(1):1228. PubMed ID: 36443704
[TBL] [Abstract][Full Text] [Related]
18. HPV Status Improves Classification of Head and Neck Gray Zone Cancers.
Ren J; Xu W; Su J; Ren X; Bender N; Habbous S; de Almeida JR; Goldstein DP; Cheng D; Chen Z; Mirshams M; Rahini M; Huang SH; Spreafico A; Hansen A; Kim J; Waldron J; Perez-Ordonez B; Zhao Y; Hung R; Waterboer T; Liu G
J Dent Res; 2019 Jul; 98(8):879-887. PubMed ID: 31282843
[TBL] [Abstract][Full Text] [Related]
19. Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial.
Sacco AG; Chen R; Worden FP; Wong DJL; Adkins D; Swiecicki P; Chai-Ho W; Oppelt P; Ghosh D; Bykowski J; Molinolo A; Pittman E; Estrada MV; Gold K; Daniels G; Lippman SM; Natsuhara A; Messer K; Cohen EEW
Lancet Oncol; 2021 Jun; 22(6):883-892. PubMed ID: 33989559
[TBL] [Abstract][Full Text] [Related]
20. Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE-012.
Tahara M; Muro K; Hasegawa Y; Chung HC; Lin CC; Keam B; Takahashi K; Cheng JD; Bang YJ
Cancer Sci; 2018 Mar; 109(3):771-776. PubMed ID: 29284202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
